These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9365799)

  • 1. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
    Masimirembwa CM; Hasler JA
    Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects.
    Bertilsson L
    Clin Pharmacol Ther; 2007 Nov; 82(5):606-9. PubMed ID: 17898711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
    Matimba A; Del-Favero J; Van Broeckhoven C; Masimirembwa C
    Hum Genomics; 2009 Jan; 3(2):169-90. PubMed ID: 19164093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
    Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
    Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
    Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
    Wadelius M; Autrup JL; Stubbins MJ; Andersson SO; Johansson JE; Wadelius C; Wolf CR; Autrup H; Rane A
    Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interethnic differences of drug-metabolizing enzymes.
    Gaedigk A
    Int J Clin Pharmacol Ther; 2000 Feb; 38(2):61-8. PubMed ID: 10706192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups.
    Luo HR; Aloumanis V; Lin KM; Gurwitz D; Wan YJ
    Am J Pharmacogenomics; 2004; 4(6):395-401. PubMed ID: 15651900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.